PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study

Background & Aims: Immune checkpoint inhibitors (ICIs) have transformed the landscape of cancer treatment, and ICI-related toxicities (i.e., immune-related adverse events (irAEs) have been reported in many clinical studies. However, the toxicity data of real-world have not been fully assessed. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Guili, Liu, Songqing, Dong, Jie, Xi, Xin, Kong, Rui, Li, Wenjun, Du, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681783/
https://www.ncbi.nlm.nih.gov/pubmed/36438818
http://dx.doi.org/10.3389/fphar.2022.974376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681783/
https://www.ncbi.nlm.nih.gov/pubmed/36438818
http://dx.doi.org/10.3389/fphar.2022.974376

Ejemplares similares